IMPACT OF THE 2017 GOLD STRATEGY ON TIOTROPIUM plus OLODATEROL RESPONSE

被引：0
|
作者：
Langton, D. [1 ,2 ]
Ferguson, G. [3 ]
Voss, F. [4 ]
Maltais, F. [5 ]
Groenke, L. [4 ]
Buhl, R. [6 ]
Watz, H. [7 ]
机构：
[1] Frankston Hosp, Thorac Med, Frankston, Vic, Australia
[2] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia
[3] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA
[4] Boehringer Ingelheim Corp, Ingelheim, Germany
[5] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada
[6] Johannes Gutenberg Univ Mainz, Mainz, Germany
[7] LungClin Grosshansdorf Pulm Res, Pulm Res Inst, Grosshansdorf, Germany
来源：
RESPIROLOGY | 2018年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
TO 129
引用
收藏
页码：90 / 90
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of tiotropium plus olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age
    Ferguson, Gary T.
    Karpel, Jill P.
    Clerisme-Beaty, Emmanuelle
    Groenke, L. Ars
    Voss, Florian
    Buhl, Roland
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 2701 - 2710
  • [42] Tiotropium plus olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo
    Singh, Dave
    Ferguson, Gary T.
    Bolitschek, Josef
    Groenke, Lars
    Hallmann, Christoph
    Bennett, Nathan
    Abrahams, Roger
    Schmidt, Olaf
    Bjermer, Leif
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [43] Determining SGRQ and TDI responder rates across the duration of clinical trials: Results from tiotropium plus olodaterol in COPD
    Derom, Eric
    Watz, Henrik
    Gronke, Lars
    Voss, Florian
    Buhl, Roland
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [44] Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)
    Buhl, Roland
    Maltais, Francois
    Abrahams, Roger
    Bjermer, Leif
    Derom, Eric
    Ferguson, Gary
    Flezar, Matjaz
    Hebert, Jacques
    McGarvey, Lorcan
    Pizzichini, Emilio
    Reid, Jim
    Veale, Antony
    Groenke, Lars
    Hamilton, Alan
    Korducki, Lawrence
    Tetzlaff, Kay
    Waitere-Wijker, Stella
    Watz, Henrik
    Bateman, Eric
    EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (04) : 969 - 979
  • [45] Analysis Of The Efficacy And Safety Of The Fixed-Dose Combination Of Tiotropium plus Olodaterol In Patients With COPD By Previous Usage Of Inhaled Corticosteroids
    Korn, S.
    Buhl, R.
    Gronke, L.
    Korducki, L.
    Amatto, V. C.
    Ferguson, G. T.
    Abrahams, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [46] A BUDGET IMPACT MODEL FOR TIOTROPIUM/OLODATEROL VERSUS FIXED-DOSE COMBINATION TRIPLE THERAPY IN PATIENTS WITH COPD
    Palli, S. R.
    Clark, B.
    VALUE IN HEALTH, 2022, 25 (07) : S431 - S431
  • [47] Pharmacokinetics and safety of tiotropium plus olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD
    Wang, Zhenlei
    Tadayasu, Yusuke
    Hu, Na
    Shu, Shiqing
    Hu, Chao
    Luo, Zhu
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2020, 63
  • [48] Tiotropium plus Olodaterol Therapy Provides Symptomatic Benefits Irrespective Of Prior Maintenance Treatment: Post Hoc Analyses Of The Otemto® Studies
    Abrahams, R.
    Ferguson, G. T.
    Bjermer, L.
    Gronke, L.
    Vob, F.
    Singh, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [49] COST-EFFECTIVENESS OF TIOTROPIUM plus OLODATEROL VERSUS ACLIDINIUM plus FORMOTEROL FIXED-DOSE COMBINATIONS IN THE MANAGEMENT OF MODERATE-TO-SEVERE COPD IN IRAN
    Taheri, S.
    Ghasemi, S. M.
    Yousefi, N.
    Peiravian, F.
    VALUE IN HEALTH, 2019, 22 : S876 - S876
  • [50] Benefits Of Tiotropium plus Olodaterol On Symptoms And Health-Related Quality Of Life In Patients With Moderate To Severe COPD With Chronic Bronchitis And/or Emphysema
    Ferguson, G. T.
    Abrahams, R.
    Bjermer, L.
    Gronke, L.
    Vob, F.
    Singh, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
12345